期刊
DIABETES
卷 60, 期 11, 页码 2872-2882出版社
AMER DIABETES ASSOC
DOI: 10.2337/db11-0876
关键词
-
资金
- Juvenile Diabetes Research Foundation
- National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (Beta Cell Biology Consortium)
- European Union [115005]
- Swiss National Science Foundation (National Centers of Competence in Research) [63]
- Swiss National Science Foundation
OBJECTIVE-To evaluate whether healthy or diabetic adult mice can tolerate an extreme loss of pancreatic a-cells and how this sudden massive depletion affects beta-cell function and blood glucose homeostasis. RESEARCH DESIGN AND METHODS-We generated a new transgenic model allowing near-total a-cell removal specifically in adult mice. Massive alpha-cell ablation was triggered in normally grown and healthy adult animals upon diphtheria toxin (DT) administration. The metabolic status of these mice was assessed in 1) physiologic conditions, 2) a situation requiring glucagon action, and 3) after beta-cell loss. RESULTS-Adult transgenic mice enduring extreme (98%) alpha-cell removal remained healthy and did not display major defects in insulin counter-regulatory response. We observed that 2% of the normal alpha-cell mass produced enough glucagon to ensure near-normal glucagonemia. beta-Cell function and blood glucose homeostasis remained unaltered after alpha-cell loss, indicating that direct local intraislet signaling between alpha- and beta-cells is dispensable. Escaping alpha-cells increased their glucagon content during subsequent months, but there was no significant alpha-cell regeneration. Near-total alpha-cell ablation did not prevent hyperglycemia in mice having also undergone massive beta-cell loss, indicating that a minimal amount of alpha-cells can still guarantee normal glucagon signaling in diabetic conditions. CONCLUSIONS-An extremely low amount of a-cells is sufficient to prevent a major counter-regulatory deregulation, both under physiologic and diabetic conditions. We previously reported that alpha-cells reprogram to insulin production after extreme beta-cell loss and now conjecture that the low alpha-cell requirement could be exploited in future diabetic therapies aimed at regenerating beta-cells by reprogramming adult alpha-cells. Diabetes 60:2872-2882, 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据